insurance coverage tirzepatide Medicaid of and Spending on GLP-1s Insurance costs got you down?

Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus and, more recently, for chronic weight management in adults with obesity or overweight with weight-related comorbidities

Obesity is a disease, and it reduces life span and compromises health. But given the expense to insurers, Dusetzina warned, if you expand the indications and extent of coverage, youll see premiums go up. For older patients, often underrepresented in clinical trials, questions about GLP-1s remain

The first and most established approach is lifestyle changes, which include diet and exercise

Notably, GLP-1-producing neurons within the nucleus tractus solitarius (NTS) project axons to the VTA and other limbic structures, further embedding GLP-1 signaling within neural networks that regulate reward and motivation (Llewellyn-Smith et al., 2011